Sugi Predict

Sugi Predict / Compounds / SCHEMBL259666

SCHEMBL259666

SCHEMBL259666

Cc1cccc(C(=O)Nc2ccccc2)c1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KCNK3 O14649 11/20 0.87
▸ KCNK9 Q9NPC2 9/20 0.87
▸ MEN1 O00255 5/20 0.87
▸ KMT2A Q03164 5/20 0.87
▸ POLB P06746 1/20 0.87
▸ KCNH2 Q12809 1/20 0.83
▸ RXFP1 Q9HBX9 1/20 0.77
▸ NPC1 O15118 3/20 0.76
▸ RAB9A P51151 3/20 0.76
▸ TP53 P04637 2/20 0.76
▸ NT5E P21589 1/20 0.73
▸ FFAR1 O14842 1/20 0.70
▸ GLA P06280 1/20 0.70
▸ L3MBTL1 Q9Y468 1/20 0.69
▸ SMN1; SMN2 Q16637 2/20 0.69
▸ HDAC1 Q13547 1/20 0.67
▸ HDAC2 Q92769 1/20 0.67
▸ HDAC8 Q9BY41 1/20 0.67
▸ HDAC6 Q9UBN7 1/20 0.67
▸ MAPT P10636 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30608967 1.00 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL19501274 0.94 KCNK3 (0.77) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL19491385 0.92 KCNK3 (0.85) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL4253897 0.91 KCNK3 (0.93) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL25863680 0.90 KMT2A (0.77) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL4257440 0.89 NPC1 (0.81) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL30048093 0.89 NPC1 (0.81) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL29434800 0.89 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL259468 0.89 KCNK3 (0.87) KCNK3KCNK9MEN1KMT2APOLB
SCHEMBL16675166 0.89 KCNK3 (0.89) KCNK3KCNK9MEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260022092-A1 PROCESS FOR SOLVENT FREE CONTINUOUS SYNTHESIS OF AMIDES AND PEPTIDES COUNCIL SCIENT IND RES (IN) 2026-01-22 — — US disclosed
EP-4555002-A1 PROCESS FOR SOLVENT FREE CONTINUOUS SYNTHESIS OF AMIDES AND PEPTIDES Council of Scientific & Industrial Research (IN) 2025-05-21 — — EP disclosed
CN-119264004-A Light-induced iridium metal catalytic synthesis method of N-aryl amide 平顶山学院 2025-01-07 — — CN disclosed
CN-118044519-A Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 科迪华农业科技有限责任公司 2024-05-17 — — CN disclosed
CN-110072842-B Molecules having pesticidal utility, and intermediates, compositions and methods related thereto 科迪华农业科技有限责任公司 2024-02-02 — — CN disclosed
WO-2024013769-A1 PROCESS FOR SOLVENT FREE CONTINUOUS SYNTHESIS OF AMIDES AND PEPTIDES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-18 — — WO disclosed
WO-2024013769-A1 PROCESS FOR SOLVENT FREE CONTINUOUS SYNTHESIS OF AMIDES AND PEPTIDES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2024-01-18 — — WO disclosed
CN-114890856-B Method for synthesizing 2,2' -biphenyl-1-carboxylic acid derivative 华南理工大学 2023-08-22 — — CN disclosed
CN-115304507-A Synthesis method of N-substituted aryl formamide 兰州石化职业技术大学 2022-11-08 — — CN disclosed
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2022-10-13 — — US disclosed
US-20070141630-A1 IDENTIFICATION OF NON-COVALENT COMPLEXES BY MASS SPECTROMETRY GENENTECH, INC. (US) 2007-06-21 — — US disclosed
US-20070141630-A1 IDENTIFICATION OF NON-COVALENT COMPLEXES BY MASS SPECTROMETRY GENENTECH, INC. (US) 2007-06-21 — — US disclosed
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases FINK CYNTHIA A 2007-03-15 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-20070037805-A1 Fused heteroaryl derivatives HAYAKAWA MASAHIKO 2007-02-15 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-7173029-B2 Fused heteroaryl derivatives ASTELLAS PHARMA INC. (JP) 2007-02-06 — — US disclosed
US-5889034-A ANTIINFLAMMATORY AGENT; ANTIATHEROSCLEROSIS AGENT; VIRICIDES WARNER-LAMBERT COMPANY (US) 1999-03-30 — — US disclosed
US-4038416-A PREVENTION AND TREATMENT OF GASTRITIS AND PEPTIC ULCER CHUGAI SEIYAKU KABUSHIKI KAISHA (JA) 1977-07-26 — — US disclosed
US-3988364-A ANTITUSSIVE AGENTS TOYO JOZO KABUSHIKI KAISHA (JA) 1976-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220324866-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK KCNK3 3283/4885KCNK9 3511/4885MEN1 4106/4885
US-20260022092-A1 PROCESS FOR SOLVENT FREE CONTINUOUS SYNTHESIS OF AMIDES AND PEPTIDES TNF, VIP, APP KCNK3 4788/4885KCNK9 4660/4885MEN1 3144/4885
US-20070037805-A1 Fused heteroaryl derivatives PIK3CD, PIK3R3, PIK3C2A KCNK3 1197/4885KCNK9 1798/4885MEN1 3330/4885
US-20070060582-A1 1,4-Disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases BRAF, RAF1, NRAS KCNK3 2969/4885KCNK9 3495/4885MEN1 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.